HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
hAGDWpaZCa14Ad3r